Diamyd Medical is hosting a webcast presentation on October 20th at 2:00 pm CET / 8:00 am EDT with Ulf Hannelius, CEO of Diamyd Medical, Josh Vieth, Director of Research at JDRF, as well as Mark Atkinson, Director for the University of Florida Diabetes Institute and member of the Board of Directors of Diamyd Medical.
The webcast will review the industry partnership between Diamyd Medical and JDRF announced in April of this year, discuss the current state of immunomodulatory approaches in Type 1 Diabetes and most notatably, the antigen-specific immunotherapy Diamyd® that is currently being evaluated in a Phase 3 trial known as DIAGNODE-3.
The presentation is hosted by News Agency Direkt and Direkt Studios and can be watched at https://www.youtube.com/watchv=mq7DE4kF7hE&ab_channel=DirektStudios.
